Stephanie Dillon
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 29 | 2026 | 3154 | 3.140 |
Why?
| | Intestinal Mucosa | 12 | 2021 | 676 | 2.590 |
Why?
| | Gastrointestinal Microbiome | 14 | 2025 | 771 | 2.570 |
Why?
| | HIV-1 | 20 | 2026 | 896 | 2.480 |
Why?
| | Dysbiosis | 9 | 2022 | 187 | 2.230 |
Why?
| | CD4-Positive T-Lymphocytes | 16 | 2026 | 1129 | 1.960 |
Why?
| | Dendritic Cells | 17 | 2020 | 499 | 1.740 |
Why?
| | Immunity, Mucosal | 5 | 2017 | 98 | 1.440 |
Why?
| | Colon | 8 | 2024 | 304 | 1.280 |
Why?
| | Gastrointestinal Tract | 5 | 2022 | 208 | 1.230 |
Why?
| | Lymphocyte Activation | 8 | 2017 | 1126 | 1.100 |
Why?
| | Microbiota | 5 | 2023 | 781 | 1.090 |
Why?
| | Bacterial Translocation | 4 | 2019 | 52 | 1.050 |
Why?
| | Interferon-gamma | 10 | 2019 | 784 | 0.850 |
Why?
| | Th1 Cells | 3 | 2019 | 139 | 0.700 |
Why?
| | Butyrates | 2 | 2021 | 67 | 0.640 |
Why?
| | Immunity, Innate | 4 | 2021 | 846 | 0.580 |
Why?
| | Th17 Cells | 1 | 2019 | 101 | 0.570 |
Why?
| | Salmonella typhimurium | 3 | 2021 | 190 | 0.550 |
Why?
| | Escherichia coli | 5 | 2014 | 854 | 0.550 |
Why?
| | Interferon Type I | 1 | 2018 | 145 | 0.520 |
Why?
| | Granzymes | 3 | 2022 | 49 | 0.490 |
Why?
| | Immunologic Factors | 1 | 2018 | 255 | 0.470 |
Why?
| | Bacteria | 3 | 2025 | 889 | 0.460 |
Why?
| | Mucous Membrane | 2 | 2015 | 127 | 0.440 |
Why?
| | Killer Cells, Natural | 2 | 2019 | 467 | 0.440 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 129 | 0.440 |
Why?
| | Interleukin-23 | 2 | 2013 | 16 | 0.420 |
Why?
| | Lymphocytes | 3 | 2021 | 382 | 0.420 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 83 | 0.410 |
Why?
| | T-Lymphocytes | 5 | 2021 | 1982 | 0.400 |
Why?
| | Aging | 2 | 2025 | 1966 | 0.390 |
Why?
| | Endotoxemia | 1 | 2014 | 87 | 0.390 |
Why?
| | Immunity | 1 | 2014 | 139 | 0.380 |
Why?
| | Flow Cytometry | 9 | 2017 | 1173 | 0.380 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2015 | 917 | 0.360 |
Why?
| | Inflammation | 5 | 2021 | 2878 | 0.360 |
Why?
| | Immune Tolerance | 3 | 2014 | 379 | 0.350 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 8 | 0.320 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 43 | 0.310 |
Why?
| | Humans | 46 | 2026 | 144759 | 0.310 |
Why?
| | Body Composition | 2 | 2026 | 706 | 0.310 |
Why?
| | Middle Aged | 22 | 2026 | 35875 | 0.310 |
Why?
| | Caspase 3 | 1 | 2010 | 238 | 0.300 |
Why?
| | Viremia | 1 | 2010 | 158 | 0.300 |
Why?
| | Myeloid Cells | 1 | 2010 | 148 | 0.300 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 240 | 0.300 |
Why?
| | Adult | 23 | 2025 | 40449 | 0.290 |
Why?
| | Ruminococcus | 2 | 2021 | 8 | 0.290 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 496 | 0.280 |
Why?
| | Interleukin-17 | 3 | 2023 | 118 | 0.280 |
Why?
| | Viral Load | 5 | 2015 | 526 | 0.280 |
Why?
| | Toll-Like Receptor 2 | 2 | 2006 | 126 | 0.270 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2026 | 177 | 0.270 |
Why?
| | Young Adult | 11 | 2020 | 14105 | 0.270 |
Why?
| | Lymphoid Tissue | 1 | 2008 | 80 | 0.270 |
Why?
| | Interferon-alpha | 2 | 2020 | 197 | 0.260 |
Why?
| | Oncogene Proteins, Viral | 1 | 2007 | 20 | 0.260 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2007 | 27 | 0.250 |
Why?
| | Human papillomavirus 16 | 1 | 2007 | 27 | 0.250 |
Why?
| | Proto-Oncogene Proteins c-fos | 2 | 2006 | 196 | 0.250 |
Why?
| | Leukocytes, Mononuclear | 5 | 2024 | 573 | 0.250 |
Why?
| | Zymosan | 1 | 2006 | 39 | 0.240 |
Why?
| | Th2 Cells | 2 | 2004 | 171 | 0.240 |
Why?
| | Apoptosis | 2 | 2014 | 2430 | 0.230 |
Why?
| | Antigen-Presenting Cells | 1 | 2006 | 160 | 0.230 |
Why?
| | High-Intensity Interval Training | 1 | 2026 | 46 | 0.230 |
Why?
| | Antiviral Agents | 3 | 2020 | 767 | 0.230 |
Why?
| | Cross-Sectional Studies | 4 | 2018 | 5868 | 0.230 |
Why?
| | Immunoglobulin A | 2 | 2022 | 214 | 0.220 |
Why?
| | Papillomavirus Infections | 2 | 2007 | 345 | 0.220 |
Why?
| | Interleukin-10 | 6 | 2013 | 309 | 0.220 |
Why?
| | Cells, Cultured | 7 | 2021 | 4154 | 0.220 |
Why?
| | Virus Replication | 3 | 2015 | 529 | 0.220 |
Why?
| | Healthy Aging | 1 | 2025 | 40 | 0.220 |
Why?
| | Interleukin-15 | 2 | 2021 | 97 | 0.210 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 377 | 0.210 |
Why?
| | Biopsy | 3 | 2018 | 1075 | 0.210 |
Why?
| | Receptors, IgG | 2 | 2014 | 76 | 0.200 |
Why?
| | Endogenous Retroviruses | 1 | 2024 | 38 | 0.200 |
Why?
| | Male | 23 | 2026 | 72315 | 0.200 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 43 | 0.200 |
Why?
| | Antigens, CD1 | 2 | 2015 | 60 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 292 | 0.190 |
Why?
| | Aged | 11 | 2026 | 25913 | 0.190 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 19 | 0.190 |
Why?
| | Female | 22 | 2026 | 78271 | 0.180 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 592 | 0.180 |
Why?
| | Arthritis, Experimental | 1 | 2023 | 141 | 0.180 |
Why?
| | MAP Kinase Signaling System | 1 | 2004 | 310 | 0.180 |
Why?
| | Interleukin-2 | 2 | 2022 | 437 | 0.180 |
Why?
| | Phenotype | 4 | 2019 | 3162 | 0.180 |
Why?
| | Acinetobacter | 1 | 2021 | 16 | 0.170 |
Why?
| | Feces | 3 | 2025 | 513 | 0.170 |
Why?
| | Glycoproteins | 2 | 2015 | 355 | 0.160 |
Why?
| | Gene Expression Profiling | 4 | 2024 | 1782 | 0.160 |
Why?
| | Antigens, CD | 3 | 2015 | 555 | 0.160 |
Why?
| | Interferon-beta | 1 | 2020 | 92 | 0.160 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1499 | 0.160 |
Why?
| | Interleukin-12 | 5 | 2012 | 117 | 0.160 |
Why?
| | Monocytes | 2 | 2013 | 538 | 0.160 |
Why?
| | Bacteria, Anaerobic | 1 | 2020 | 25 | 0.160 |
Why?
| | Adaptive Immunity | 1 | 2021 | 169 | 0.150 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2025 | 558 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 220 | 0.150 |
Why?
| | Membrane Proteins | 1 | 2006 | 1166 | 0.150 |
Why?
| | Aged, 80 and over | 3 | 2021 | 8265 | 0.150 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2019 | 92 | 0.140 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 47 | 0.140 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 81 | 0.140 |
Why?
| | CD4 Lymphocyte Count | 3 | 2014 | 277 | 0.140 |
Why?
| | Diet, High-Fat | 1 | 2019 | 261 | 0.140 |
Why?
| | Interleukins | 1 | 2019 | 248 | 0.130 |
Why?
| | Antigen Presentation | 1 | 1998 | 205 | 0.130 |
Why?
| | Immunoglobulins | 2 | 2015 | 160 | 0.130 |
Why?
| | CD40 Antigens | 2 | 2015 | 90 | 0.130 |
Why?
| | GPI-Linked Proteins | 2 | 2014 | 80 | 0.130 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 94 | 0.130 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2021 | 233 | 0.120 |
Why?
| | Case-Control Studies | 4 | 2020 | 3604 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2021 | 2496 | 0.120 |
Why?
| | Age Factors | 3 | 2019 | 3333 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 342 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2017 | 521 | 0.110 |
Why?
| | Prevotella | 1 | 2015 | 26 | 0.110 |
Why?
| | Tuberculosis | 1 | 1998 | 291 | 0.110 |
Why?
| | Immunophenotyping | 2 | 2014 | 322 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 138 | 0.110 |
Why?
| | Colitis | 1 | 2017 | 280 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1169 | 0.110 |
Why?
| | Receptors, Peptide | 1 | 2014 | 18 | 0.100 |
Why?
| | CD56 Antigen | 1 | 2014 | 35 | 0.100 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 28 | 0.100 |
Why?
| | Exercise | 1 | 2026 | 2201 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 824 | 0.100 |
Why?
| | Intestines | 1 | 2017 | 358 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 2 | 2014 | 415 | 0.100 |
Why?
| | Cell Separation | 2 | 2014 | 307 | 0.100 |
Why?
| | Cell Lineage | 1 | 2015 | 376 | 0.100 |
Why?
| | Spleen | 2 | 2006 | 508 | 0.100 |
Why?
| | Homeostasis | 1 | 2017 | 640 | 0.090 |
Why?
| | Lipoproteins | 2 | 2004 | 169 | 0.090 |
Why?
| | Bacteroides fragilis | 1 | 2012 | 14 | 0.090 |
Why?
| | Fetal Tissue Transplantation | 2 | 2003 | 33 | 0.090 |
Why?
| | Phylogeny | 1 | 2017 | 1016 | 0.090 |
Why?
| | Enterococcus | 1 | 2012 | 22 | 0.090 |
Why?
| | Cytokines | 3 | 2010 | 2061 | 0.090 |
Why?
| | Lymphocyte Depletion | 1 | 2012 | 132 | 0.090 |
Why?
| | Pilot Projects | 1 | 2017 | 1886 | 0.090 |
Why?
| | Lipopolysaccharides | 2 | 2006 | 863 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2006 | 2182 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2024 | 2608 | 0.080 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 22 | 0.080 |
Why?
| | Diet | 2 | 2019 | 1273 | 0.080 |
Why?
| | Biodiversity | 1 | 2014 | 426 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2006 | 3121 | 0.080 |
Why?
| | Signal Transduction | 4 | 2021 | 5226 | 0.080 |
Why?
| | Mice | 8 | 2023 | 18339 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2009 | 47 | 0.070 |
Why?
| | Mice, Inbred C57BL | 4 | 2006 | 5992 | 0.070 |
Why?
| | Chemotaxis | 1 | 2009 | 122 | 0.070 |
Why?
| | Toll-Like Receptor 4 | 2 | 2013 | 276 | 0.070 |
Why?
| | Interleukin-1beta | 2 | 2019 | 395 | 0.060 |
Why?
| | DNA Primers | 1 | 2008 | 512 | 0.060 |
Why?
| | Hepatitis C, Chronic | 1 | 2009 | 152 | 0.060 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 175 | 0.060 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 186 | 0.060 |
Why?
| | Capsid Proteins | 1 | 2007 | 95 | 0.060 |
Why?
| | Animals | 9 | 2023 | 38058 | 0.060 |
Why?
| | Lectins, C-Type | 1 | 2006 | 62 | 0.060 |
Why?
| | Yeasts | 1 | 2006 | 52 | 0.060 |
Why?
| | HIV | 1 | 2007 | 250 | 0.060 |
Why?
| | Ligands | 2 | 2007 | 673 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 1217 | 0.060 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2006 | 66 | 0.060 |
Why?
| | Parkinson Disease | 2 | 2003 | 600 | 0.060 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2007 | 202 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 173 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2006 | 370 | 0.060 |
Why?
| | Absorptiometry, Photon | 1 | 2026 | 276 | 0.060 |
Why?
| | Body Mass Index | 1 | 2014 | 2438 | 0.060 |
Why?
| | Adolescent | 2 | 2019 | 22428 | 0.050 |
Why?
| | Base Sequence | 1 | 2008 | 2190 | 0.050 |
Why?
| | Genes, Immediate-Early | 1 | 2004 | 26 | 0.050 |
Why?
| | Enzyme Induction | 1 | 2004 | 88 | 0.050 |
Why?
| | Vaccines, DNA | 1 | 2004 | 31 | 0.050 |
Why?
| | CD11c Antigen | 1 | 2004 | 40 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2004 | 77 | 0.050 |
Why?
| | CD11b Antigen | 1 | 2004 | 60 | 0.050 |
Why?
| | Dipeptides | 1 | 2004 | 57 | 0.050 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2024 | 32 | 0.050 |
Why?
| | Retroelements | 1 | 2024 | 51 | 0.050 |
Why?
| | Ovalbumin | 1 | 2004 | 190 | 0.050 |
Why?
| | Dopamine | 2 | 2003 | 283 | 0.050 |
Why?
| | Papillomaviridae | 1 | 2004 | 115 | 0.050 |
Why?
| | Anti-Allergic Agents | 1 | 2003 | 40 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 175 | 0.050 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2004 | 114 | 0.050 |
Why?
| | Resistance Training | 1 | 2026 | 182 | 0.050 |
Why?
| | Protein Subunits | 1 | 2004 | 226 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 479 | 0.050 |
Why?
| | Toll-Like Receptors | 1 | 2004 | 194 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2004 | 206 | 0.050 |
Why?
| | Neurons | 2 | 2003 | 1640 | 0.050 |
Why?
| | Viral Vaccines | 1 | 2004 | 107 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2004 | 161 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2007 | 672 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2007 | 893 | 0.050 |
Why?
| | Tryptophan | 1 | 2023 | 181 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 2050 | 0.050 |
Why?
| | Immunoglobulin E | 1 | 2003 | 315 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2006 | 780 | 0.040 |
Why?
| | Frailty | 1 | 2025 | 198 | 0.040 |
Why?
| | Time Factors | 2 | 2006 | 7173 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2022 | 120 | 0.040 |
Why?
| | Propionates | 1 | 2021 | 39 | 0.040 |
Why?
| | Control Groups | 1 | 2001 | 12 | 0.040 |
Why?
| | Brain Tissue Transplantation | 1 | 2001 | 19 | 0.040 |
Why?
| | Eosinophilia | 1 | 2003 | 221 | 0.040 |
Why?
| | Collagen | 1 | 2023 | 456 | 0.040 |
Why?
| | Acetates | 1 | 2021 | 80 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2004 | 427 | 0.040 |
Why?
| | Mesencephalon | 1 | 2001 | 64 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 252 | 0.040 |
Why?
| | Papillomavirus Vaccines | 1 | 2004 | 297 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2003 | 1253 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1732 | 0.040 |
Why?
| | Immunologic Memory | 2 | 2014 | 366 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 81 | 0.040 |
Why?
| | Tuberculin | 1 | 1998 | 8 | 0.040 |
Why?
| | Freund's Adjuvant | 1 | 1998 | 18 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2019 | 60 | 0.040 |
Why?
| | Models, Biological | 1 | 2006 | 1821 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2019 | 235 | 0.030 |
Why?
| | HIV Seropositivity | 1 | 2019 | 119 | 0.030 |
Why?
| | Macrophages | 1 | 2006 | 1511 | 0.030 |
Why?
| | Up-Regulation | 2 | 2014 | 851 | 0.030 |
Why?
| | Metagenome | 1 | 2019 | 149 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2021 | 668 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2006 | 2363 | 0.030 |
Why?
| | Metagenomics | 1 | 2019 | 181 | 0.030 |
Why?
| | Epitopes | 1 | 1998 | 485 | 0.030 |
Why?
| | Disease Progression | 2 | 2019 | 2847 | 0.030 |
Why?
| | Histones | 1 | 2021 | 669 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2019 | 652 | 0.030 |
Why?
| | Virion | 1 | 2015 | 111 | 0.030 |
Why?
| | Cohort Studies | 1 | 2025 | 5960 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 680 | 0.030 |
Why?
| | Caspase 1 | 1 | 2014 | 148 | 0.020 |
Why?
| | Antigens, CD19 | 1 | 2014 | 129 | 0.020 |
Why?
| | Biomarkers | 2 | 2019 | 4271 | 0.020 |
Why?
| | Tomography, Emission-Computed | 2 | 2003 | 71 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1047 | 0.020 |
Why?
| | Chronic Disease | 2 | 2009 | 1813 | 0.020 |
Why?
| | Blood | 1 | 2012 | 109 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1887 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1098 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 1045 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 53 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 177 | 0.020 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 37 | 0.020 |
Why?
| | Gene Products, gag | 1 | 2007 | 38 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 2168 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2003 | 2029 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 242 | 0.010 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2007 | 264 | 0.010 |
Why?
| | B7-H1 Antigen | 1 | 2007 | 241 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2007 | 502 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 2004 | 77 | 0.010 |
Why?
| | CD11 Antigens | 1 | 2004 | 30 | 0.010 |
Why?
| | Genotype | 1 | 2009 | 1833 | 0.010 |
Why?
| | Schistosoma mansoni | 1 | 2003 | 41 | 0.010 |
Why?
| | Putamen | 1 | 2003 | 22 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2004 | 275 | 0.010 |
Why?
| | Antigens, Viral | 1 | 2004 | 182 | 0.010 |
Why?
| | Antiparkinson Agents | 1 | 2003 | 41 | 0.010 |
Why?
| | Interleukin-4 | 1 | 2004 | 206 | 0.010 |
Why?
| | Craniotomy | 1 | 2003 | 82 | 0.010 |
Why?
| | Models, Animal | 1 | 2004 | 392 | 0.010 |
Why?
| | Treatment Failure | 1 | 2003 | 365 | 0.010 |
Why?
| | Dihydroxyphenylalanine | 1 | 2001 | 9 | 0.010 |
Why?
| | Viral Proteins | 1 | 2004 | 355 | 0.010 |
Why?
| | Culture Techniques | 1 | 2001 | 67 | 0.010 |
Why?
| | Fluorine Radioisotopes | 1 | 2001 | 13 | 0.010 |
Why?
| | Allergens | 1 | 2003 | 384 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 1266 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 2882 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2003 | 1134 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2004 | 3409 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2009 | 11679 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2001 | 2925 | 0.010 |
Why?
| | Brain | 1 | 2001 | 2933 | 0.000 |
Why?
|
|
Dillon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|